WO2021141634A3 - Systems and methods for using biomarker analysis for personalized skincare - Google Patents

Systems and methods for using biomarker analysis for personalized skincare Download PDF

Info

Publication number
WO2021141634A3
WO2021141634A3 PCT/US2020/042012 US2020042012W WO2021141634A3 WO 2021141634 A3 WO2021141634 A3 WO 2021141634A3 US 2020042012 W US2020042012 W US 2020042012W WO 2021141634 A3 WO2021141634 A3 WO 2021141634A3
Authority
WO
WIPO (PCT)
Prior art keywords
skincare
skin
skincare product
subject
systems
Prior art date
Application number
PCT/US2020/042012
Other languages
French (fr)
Other versions
WO2021141634A2 (en
Inventor
Ji Lee
Guive BALOOCH
Aude FOUCHER
Nukhet Cavusoglu
Fred Orsita
Edouard MESSAGER
Original Assignee
L'oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/528,380 external-priority patent/US11741523B2/en
Priority claimed from US16/528,196 external-priority patent/US11501356B2/en
Application filed by L'oreal filed Critical L'oreal
Priority to CN202080062859.9A priority Critical patent/CN114828735A/en
Priority to JP2022506506A priority patent/JP7467594B2/en
Priority to EP20883687.4A priority patent/EP4004932A2/en
Priority to KR1020227006298A priority patent/KR20220038470A/en
Publication of WO2021141634A2 publication Critical patent/WO2021141634A2/en
Publication of WO2021141634A3 publication Critical patent/WO2021141634A3/en
Priority to JP2024060132A priority patent/JP2024081779A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B19/00—Programme-control systems
    • G05B19/02—Programme-control systems electric
    • G05B19/18—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of programme data in numerical form
    • G05B19/414—Structure of the control system, e.g. common controller or multiprocessor systems, interface to servo, programmable interface controller
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0278—Product appraisal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0621—Item configuration or customization
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Item recommendations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00—Program-control systems
    • G05B2219/30—Nc systems
    • G05B2219/32—Operator till task planning
    • G05B2219/32287—Medical, chemical, biological laboratory
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Business, Economics & Management (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Accounting & Taxation (AREA)
  • Finance (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Strategic Management (AREA)
  • Development Economics (AREA)
  • Pathology (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Business, Economics & Management (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)

Abstract

Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients. In some embodiments, protein biomarker concentration information for a subject is obtained, and is used to determine one or more skin trends likely to be experienced by the subject. Skincare product recommendations are generated based on the protein biomarker concentration information. Feedback on the recommended skincare products may be received, and may be used to improve future recommendations for skincare products for the subject or for other subjects.
PCT/US2020/042012 2019-07-31 2020-07-14 Systems and methods for using biomarker analysis for personalized skincare WO2021141634A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202080062859.9A CN114828735A (en) 2019-07-31 2020-07-14 Systems and methods for personalized skin care using biomarker analysis
JP2022506506A JP7467594B2 (en) 2019-07-31 2020-07-14 Systems and methods for using biomarker analysis for personalized skin care - Patents.com
EP20883687.4A EP4004932A2 (en) 2019-07-31 2020-07-14 Systems and methods for using biomarker analysis for personalized skincare
KR1020227006298A KR20220038470A (en) 2019-07-31 2020-07-14 Systems and methods for using biomarker analysis for personalized skincare
JP2024060132A JP2024081779A (en) 2019-07-31 2024-04-03 Systems and methods for using biomarker analysis for personalized skincare

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16/528,380 US11741523B2 (en) 2019-07-31 2019-07-31 Personalized skincare recommendations based on biomarker analysis
US16/528,196 US11501356B2 (en) 2019-07-31 2019-07-31 Systems and methods for generating personalized skincare formulations based on biomarker analysis
US16/528,380 2019-07-31
US16/528,196 2019-07-31

Publications (2)

Publication Number Publication Date
WO2021141634A2 WO2021141634A2 (en) 2021-07-15
WO2021141634A3 true WO2021141634A3 (en) 2021-09-16

Family

ID=75825823

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/042012 WO2021141634A2 (en) 2019-07-31 2020-07-14 Systems and methods for using biomarker analysis for personalized skincare

Country Status (5)

Country Link
EP (1) EP4004932A2 (en)
JP (2) JP7467594B2 (en)
KR (1) KR20220038470A (en)
CN (1) CN114828735A (en)
WO (1) WO2021141634A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154557A1 (en) * 2022-02-14 2023-08-17 Washington University Methods for detecting surgical drain fluid exosomes and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131902A1 (en) * 2003-09-07 2008-06-05 Ahava-Dead Sea Laboratories Ltd. Personalized skin care composition and method for production thereof
KR20130135887A (en) * 2010-12-13 2013-12-11 로레알 Use of ide as a biomarker for a scalp condition
WO2018187151A1 (en) * 2017-04-03 2018-10-11 L'oreal System for forming a cosmetic composition and skin care management system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0806109A2 (en) * 2007-01-05 2011-08-30 Myskin Inc dermal imaging system, device and method
JP6022260B2 (en) * 2012-08-22 2016-11-09 ロート製薬株式会社 Evaluation method of skin condition
EP3690439B1 (en) * 2013-03-15 2024-03-27 The Procter & Gamble Company A noninvasive method for measuring metabolites for skin health

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131902A1 (en) * 2003-09-07 2008-06-05 Ahava-Dead Sea Laboratories Ltd. Personalized skin care composition and method for production thereof
KR20130135887A (en) * 2010-12-13 2013-12-11 로레알 Use of ide as a biomarker for a scalp condition
WO2018187151A1 (en) * 2017-04-03 2018-10-11 L'oreal System for forming a cosmetic composition and skin care management system

Also Published As

Publication number Publication date
CN114828735A (en) 2022-07-29
EP4004932A2 (en) 2022-06-01
KR20220038470A (en) 2022-03-28
JP7467594B2 (en) 2024-04-15
JP2024081779A (en) 2024-06-18
WO2021141634A2 (en) 2021-07-15
JP2022542457A (en) 2022-10-03

Similar Documents

Publication Publication Date Title
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
Coughlin et al. The preadolescent acne microbiome: a prospective, randomized, pilot study investigating characterization and effects of acne therapy
WO2014153466A3 (en) Methods and tools for analyzing brain images
MX2018014405A (en) Apparatus and method for customizing products on a regional basis.
WO2015120243A8 (en) Application execution control utilizing ensemble machine learning for discernment
Miller et al. Cognitive complexity as a function of the significance of the stimulus objects being judged
WO2014074338A3 (en) Systems and methods for calculating glycemic variability
BR112018015698A2 (en) ? diagnostic and prognostic methods for cardiovascular disease and events?
BR112015007951A2 (en) Weather display method and apparatus
MX2022007125A (en) Classification models for analyzing a sample.
PH12020550131A1 (en) Natural language processing and analysis in a conversational scheduling assistant computing system
WO2019028470A3 (en) Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
WO2021141634A3 (en) Systems and methods for using biomarker analysis for personalized skincare
Bao et al. Serum levels and activity of indoleamine2, 3-dioxygenase and tryptophanyl-tRNA synthetase and their association with disease severity in patients with chronic kidney disease
Rostoff et al. Value of lead aVR in the detection of significant left main coronary artery stenosis in acute coronary syndrome
BR112014012003A2 (en) computer readable quality control method, method and medium for use with consumer goods, users and biological / environmental diagnostic test devices
Shi et al. The relationship of the geriatric nutritional risk index to mortality and length of stay in elderly patients with acute respiratory failure: a retrospective cohort study
WO2020094954A3 (en) Method for assessing the ability of a substance or of a composition to prevent, slow or eliminate the signs of ageing of the skin or of the lips
El-Mongy et al. Serum 25-hydroxy vitamin D3 level in Egyptian patients with alopecia areata
FI20175862A1 (en) System for determining sound source
Harrold et al. Velocity, occlusion, and sex of subjects in coincidence of anticipation
Webb et al. Repeatable techniques for assessing changes in passive swimming resistance
MX2022004017A (en) Detection of analytes by protein switches.
WO2020139259A3 (en) System and method for detecting the user habits and identifying the user
Bergly et al. The predictive validity of the URICA in a sample of patients in substance use treatment

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2022506506

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20227006298

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020883687

Country of ref document: EP

Effective date: 20220228

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20883687

Country of ref document: EP

Kind code of ref document: A2